Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib

Cancer Research

Volumn 71, Issue 2, 2011, Pages 383-392

  Chang, Wen Hsin ^a   Liu, Ta Chih ^a,b,c   Yang, Wen Kuang ^d   Lee, Chien Chih ^c   Lin, Yi Hsiung ^c   Chen, Tsai Yun ^e   Chang, Jan Gowth ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BCR ABL PROTEIN; CRK LIKE PROTEIN; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; IMATINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN BCL 2; PROTEIN BCL X; SERINE ARGININE RICH PROTEIN; SURVIVIN;

ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; CELL MUTANT; CELL STRAIN K 562; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PH; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GENE;

ALTERNATIVE SPLICING; AMILORIDE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL CYCLE; DRUG SYNERGISM; EXONS; FUSION PROTEINS, BCR-ABL; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEINS; HL-60 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NUCLEAR PROTEINS; PIPERAZINES; PROTEIN PHOSPHATASE 1; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; RNA-BINDING PROTEINS;

EID: 78751562185     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1037     Document Type: Article

References (39)

1. Mayeda A, Helfman DM, Krainer AR. Modulation of exon skipping and inclusion by heterogeneous nuclear ribonucleoprotein A1 and premRNA splicing factor SF2/ASF. Mol Cell Biol 1993;13:2993-3001.
2. Stamm S. Regulation of alternative splicing by reversible protein phosphorylation. J Biol Chem 2008;283:1223-7.
3. Caceres JF, Kornblihtt AR. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 2002;18:186-93.
4. Schwerk C, Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell 2005;19:1-13.
5. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
6. Benito A, Silva M, Grillot D, Nunez G, Fernandez-Luna JL. Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-XL. Blood 1996;87:3837-43.
7. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81: 3091-6.
8. Stoetzer OJ, Nussler V, Darsow M, Gullis E, Pelka-Fleischer R, Scheel U, et al. Association of bcl-2, bax, bcl-xL and interleukin-1 betaconverting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia 1996;10Suppl3:S18-22.
9. Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 1998;9:159-65.
10. Bincoletto C, Saad ST, da Silva ES, Queiroz ML. Haematopoietic response and bcl-2 expression in patients with acute myeloid leukaemia. Eur J Haematol 1999;62:38-42.
11. Liu R, Page C, Beidler DR, Wicha MS, Nunez G. Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model. Am J Pathol 1999;155:1861-7.
12. Tu Y, Renner S, Xu F, Fleishman A, Taylor J, Weisz J, et al. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 1998;58:256-62.
13. Sumantran VN, Ealovega MW, Nunez G, Clarke MF, Wicha MS. Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapyinduced apoptosis. Cancer Res 1995;55:2507-10.
14. Taylor JK, Zhang QQ, Monia BP, Marcusson EG, Dean NM. Inhibition of Bcl-xL expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli. Oncogene 1999;18:4495-504.
15. Bull MB, Laragh JH. Amiloride. A potassium-sparing natriuretic agent. Circulation 1968;37:45-53.
16. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-5.
17. La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002;62:7149-53.
18. Yuo CY, Lin HH, Chang YS, Yang WK, Chang JG. 5-(N-Ethyl-Nisopropyl)- amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells. Ann Neurol 2008;63:26-34.
19. Cao W, Jamison SF, Garcia-Blanco MA. Both phosphorylation and dephosphorylation of ASF/SF2 are required for pre-mRNA splicing in vitro. RNA 1997;3:1456-67.
20. Blaustein M, Pelisch F, Tanos T, Munoz MJ, Wengier D, Quadrana L, et al. Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nat Struct Mol Biol 2005;12:1037-44.
21. Cohen P, Klumpp S, Schelling DL. An improved procedure for identifying and quantitating protein phosphatases in mammalian tissues. FEBS Lett 1989;250:596-600.
22. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-31.
23. Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2008;22:954-65.
24. Chen YC, Yuo CY, Yang WK, Jong YJ, Lin HH, Chang YS, et al. Extracellular pH change modulates the exon 7 splicing in SMN2mRNA. Mol Cell Neurosci 2008;39:268-72.
25. Borsi L, Balza E, Gaggero B, Allemanni G, Zardi L. The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH. J Biol Chem 1995;270:6243-5.
26. + exchanger. Leukoc Res 2007;31:507-14.
27. Chalfant CE, Rathman K, Pinkerman RL, Wood RE, Obeid LM, Ogretmen B, et al. De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem 2002;277:12587-95.
28. Yang H, Sadda MR, Li M, Zeng Y, Chen L, Bae W, et al. S-Adenosylmethionine and its metabolite induce apoptosis in HepG2 cells: role of protein phosphatase 1 and Bcl-x(S). Hepatology 2004;40:221-31.
29. Boon-Unge K, Yu Q, Zou T, Zhou A, Govitrapong P, Zhou J. Emetine regulates the alternative splicing of Bcl-x through a protein phosphatase 1-dependent mechanism. Chem Biol 2007;14:1386-92.
30. Lauber K, Appel HA, Schlosser SF, Gregor M, Schulze-Osthoff K, Wesselborg S. The adapter protein apoptotic protease-activating factor-1 (Apaf-1) is proteolytically processed during apoptosis. J Biol Chem 2001;276:29772-81.
31. Takino T, Nakada M, Miyamori H, Yamashita J, Yamada KM, Sato H. CrkI adapter protein modulates cell migration and invasion in glioblastoma. Cancer Res 2003;63:2335-7.
32. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54.
33. Noton EA, Colnaghi R, Tate S, Starck C, Carvalho A, Ko Ferrigno P, et al. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 2006;281:1286-95.
34. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56.
35. Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grunebach F, et al. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res 2007;67: 5489-97.
36. Arana-Trejo RM, Ruiz Sanchez E, Ignacio-Ibarra G, Baez de la Fuente E, Garces O, Gomez Morales E, et al. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML). Clin Lab Haematol 2002;24:145-50.
37. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001;97:1999-2007.
38. Smith AJ, Smith RN. Kinetics and bioavailability of two formulations of amiloride in man. Br J Pharmacol 1973;48:646-9.
39. Qasqas SA, McPherson C, Frishman WH, Elkayam U. Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation. Cardiol Rev 2004;12:240-61.